| Name | Title | Contact Details |
|---|
Nightstar is a private biopharmaceutical company focused on the development of therapies for retinal dystrophies. The Company’s lead programme is a retinal gene therapy for choroideremia, a rare inherited cause of blindness that affects around 1 in 50,000 people. Gene therapy has the potential to be an effective treatment for choroideremia and a range of other retinal dystrophies. The Company’s lead investors are Syncona LLP and NEA Inc. Syncona is an evergreen investment company, taking an active role in identifying, supporting and developing technologies with the potential to impact significantly the healthcare market of the future. NEA is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies.
Monogram Biosciences, Inc. (Monogram) is a life sciences company committed to advancing personalized medicine and improving patient outcomes through the development of molecular diagnostic products that guide and target the appropriate treatments
A paradigm shift in prosthetic comfort and quality of life. The Socket-less Socket™ fits like a sneaker providing comfort and control for all amputation levels.
Compass Health Northwest Washington’s Behavioral Healthcare Leader Access Services Compass Health provides comprehensive services to treat behavioral health…